It may either reflect a synergistic risk of combining low right CCA MFV and hypertension on CHD development [11], or just reflect a confounding background with a high percentage of using β-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor antagonists, which are traditionally recommended in patients with confirmed CHD [16]. The gene discussed is ACE; the disease is coronary artery disorder.